Archives

by in
Entry Author Date Location
BIO 2014: Why San Diego is a Hub for RNA R&D and Drug Development 06/23/14 San Diego
RNA Therapeutics Are Here to Stay 06/05/14 San Diego
West Coast Biotech Roundup: Lumena/Shire, Isis, Janssen Labs & More 05/16/14 San Diego
Biogen Idec Strikes $100M Upfront Deal With Isis for Neurology 09/09/13 Boston
San Diego Life Sciences Roundup: Arena, Organovo, Isis, & More 06/13/13 San Diego
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
Isis Execs Upbeat as AstraZeneca Expands Cancer Drug Collaboration 06/05/13 San Diego
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego 06/03/13 San Diego
Roche & Isis Join Forces on Antisense Drug for Huntington’s Disease 04/08/13 San Diego
RNA Therapeutics Are Coming of Age 02/08/13 San Diego
San Diego Life Sciences Roundup: Isis, Afraxis, Organovo, & More 01/31/13 San Diego
Isis Pharmaceuticals Adds More Deals to Partnership Portfolio 12/12/12 San Diego
BioPharma Needs A Safe, Reliable Way To Repair Broken Genes 04/11/12 Seattle
Buyouts, Quantified Health, & More San Diego Life Sciences News 12/01/11 San Diego
Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring 11/22/11 San Diego
Isis Nabs $35M Payment From Glaxo 03/31/10 San Diego
Five Biotechnologies That Will Fade Away This Decade 01/06/10 National
Isis, Genzyme Use Antisense to Go Where Many Drugs Fail—The Brain 08/05/09 San Diego
Isis, Alnylam to Collaborate on Single-Stranded RNA Drugs; Deal Could Add Up to $31 Million to Isis’ Coffers 04/29/09 San Diego
Genzyme Places Big Bet on Antisense RNA With Isis Deal 01/08/08 Boston
RNAi Firms Find a New Rival (and Partner) in an Old Technology 10/04/07 Boston
Page 1 of 1